🇺🇸 LLY — Eli Lilly and Company

Healthcare Compra
← Volver

Precio actual

1.149,36 USD

Máx. histórico

1.292,65

16 días

Split 2:1 del 16/10/1997

Caída desde máximo

-11,08%

Rango 52 semanas

712,05 – 1.292,65

Variación hoy

-0,88%

Cierre anterior

1.159,60

Rango de hoy

1.138,31 – 1.158,43

Volumen hoy

2.159.931

Información
Nombre completo
Eli Lilly and Company
Divisa
USD
Mercado
NYSE
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
50.000
PER ⓘ
38,61 (puede no estar actualizado)
Dividend yield
0,60% (puede no estar actualizado)
Precio objetivo analistas
1.315,56 USD (puede no estar actualizado)
Primera cotización
01/06/1972
Precio actualizado
hace 3 días
Sobre la empresa

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Dividendos repartidos Total últimos 12 meses: 6,6900 USD · Yield: 0,58%
Fecha de pago Importe por participación
14/05/2015 0,5000 USD
11/02/2015 0,5000 USD
12/11/2014 0,4900 USD
13/08/2014 0,4900 USD
13/05/2014 0,4900 USD
12/02/2014 0,4900 USD
13/11/2013 0,4900 USD
13/08/2013 0,4900 USD
14/05/2013 0,4900 USD
13/02/2013 0,4900 USD
13/11/2012 0,4900 USD
13/08/2012 0,4900 USD
11/05/2012 0,4900 USD
13/02/2012 0,4900 USD
10/11/2011 0,4900 USD
Splits Registrados en el histórico de precios
Fecha Ratio
16/10/1997 2:1
21/12/1995 2:1
01/05/1989 2:1
30/01/1986 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
14/04/2011 35,61 35,90 35,45 35,75 +0,20% 1,26% 9.595.100
13/04/2011 35,90 35,94 35,64 35,68 -0,45% 0,84% 5.063.400
12/04/2011 35,76 36,04 35,72 35,84 -0,08% 0,89% 3.578.300
11/04/2011 35,78 36,05 35,73 35,87 +0,50% 0,89% 5.675.500
08/04/2011 35,85 35,85 35,58 35,69 -0,11% 0,75% 6.119.100
07/04/2011 35,66 35,79 35,47 35,73 +0,03% 0,90% 6.786.600
06/04/2011 35,09 35,80 35,09 35,72 +2,03% 2,02% 10.337.600
05/04/2011 34,96 35,25 34,95 35,01 -0,06% 0,86% 4.158.100
04/04/2011 35,12 35,18 34,97 35,03 +0,11% 0,60% 5.073.200
01/04/2011 35,21 35,28 34,88 34,99 -0,51% 1,14% 6.385.300
31/03/2011 35,26 35,42 35,16 35,17 -0,03% 0,74% 5.860.800
30/03/2011 34,87 35,23 34,79 35,18 +1,44% 1,26% 6.180.700
29/03/2011 34,38 34,71 34,33 34,68 +0,78% 1,11% 4.423.200
28/03/2011 34,46 34,63 34,38 34,41 -0,20% 0,73% 5.009.800
25/03/2011 34,59 34,71 34,45 34,48 -0,35% 0,75% 4.750.700
24/03/2011 34,44 34,70 34,32 34,60 +0,70% 1,10% 3.466.800
23/03/2011 34,48 34,52 34,17 34,36 -0,61% 1,02% 3.677.300
22/03/2011 34,56 34,75 34,50 34,57 +0,55% 0,72% 3.995.800
21/03/2011 34,75 34,75 34,37 34,38 -0,29% 1,09% 4.656.600
18/03/2011 34,48 34,52 34,22 34,48 +1,03% 0,87% 6.271.000
17/03/2011 33,86 34,28 33,86 34,13 +1,49% 1,24% 16.946.300
16/03/2011 34,10 34,10 33,46 33,63 -1,38% 1,88% 8.771.200
15/03/2011 34,16 34,35 34,00 34,10 -1,81% 1,02% 7.572.000
14/03/2011 34,69 34,89 34,56 34,73 -0,37% 0,95% 11.484.600
11/03/2011 34,89 35,00 34,70 34,86 +0,26% 0,86% 5.137.800
10/03/2011 35,10 35,20 34,74 34,77 -0,91% 1,31% 5.660.700
09/03/2011 34,91 35,18 34,86 35,09 +0,31% 0,92% 4.693.100
08/03/2011 34,67 35,10 34,57 34,98 +0,92% 1,53% 6.907.800
07/03/2011 34,61 34,78 34,50 34,66 +0,17% 0,81% 7.097.800
04/03/2011 34,44 34,70 34,40 34,60 +0,61% 0,87% 6.903.800